Jump to content
  • Posts

    • image courtesy of Cognitune "Turmeric can even help prevent acne, cancer, allergies, diabetes, joint pain, and depression." 10 Health Benefits and Uses for Turmeric Curcumin Supplements, Cognitune Smarter Health
    • RedMage, 
      This paper is not a double blind, placebo controlled study on rosacea and diet. As it explains, it was "collected by standardized questionnaires." So the results are based upon anecdotal reports, and none of these 'patients with rosacea' were in a clinical laboratory with controls on what they ate and drank. They simply answered questions on a form. How can anyone be sure that the patients answered correctly or omitted pertinent data?  While the data collected may be helpful, since there are rarely any papers on diet and rosacea, at least they have made an attempt at the task which is monumental, and the paper is interesting, to say the least.   So when the report says "high-frequency dairy product intake showed negative correlations with ETR and papulopustular rosacea" does it differentiate between ice cream with heavy amounts of sugar or just plain heavy cream without sugar?  There is a big difference. If you took one hundred rosaceans and had them just eat heavy cream for a week and see the results with another group that just ate ice cream for a week you might notice differences. Or compare one hundred rosaceans eating just cheese for a week with a group of a hundred rosaceans who just eat milk shakes.  As for the fatty food and tea, again, there really aren't any controls, and the data could be biased since it is anecdotal. Possibly the one good item about this report is that it may stimulate more papers on diet and rosacea. Most rosaceans have a gut feeling about their rosacea, while other rosaceans report that diet has no effect on their rosacea.  A real clinical study on rosacea and diet hasn't been done yet. Wouldn't it be something if a non profit organization for rosacea patient advocacy could get 10,000 rosacea sufferers together into one group and conduct their own research (say each one donated $1) on diet and rosacea. 
    • Does it mean that for ETR we should eat dairy based food and cut any fatty food and tea?    
    • Related Articles Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatol Sci. 2018 Dec 28;: Authors: Choi JE, Werbel T, Wang Z, Wu CC, Yaksh TL, Di Nardo A Abstract
      BACKGROUND: Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.
      OBJECTIVES: To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.
      METHODS: Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.
      RESULTS: Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.
      CONCLUSIONS: These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study.
      PMID: 30658871 [PubMed - as supplied by publisher] {url} = URL to article
    • Related Articles Sarecycline: First Global Approval. Drugs. 2019 Jan 18;: Authors: Deeks ED Abstract
      Sarecycline (Seysara™) is an oral, once-daily, tetracycline-class drug for which a tablet formulation is approved in the USA for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged ≥ 9 years. The drug was developed by Paratek and Allergen and later acquired by Almirall S.A. (a Barcelona-based pharmaceutical company focused on medical dermatology). Sarceycline tablets were approved in early October 2018 and are planned to be available for patients in January 2019. Sarecycline capsules have also been studied in the USA, but no recent reports of development have been identified for this formulation. There are currently no clinical trials underway assessing sarecycline in rosacea. This article summarizes the milestones in the development of sarecycline leading to this first approval for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
      PMID: 30659422 [PubMed - as supplied by publisher] {url} = URL to article